Bad News
The monovalent XBB.1.5 doesn't seem to offer much immunity against the new variant JN.1, according to a new study from the The Sato Lab (Kei Sato).
From a tweet:
"JN.1 shows a robust resistance to monovalent XBB.1.5 vaccine sera. These results suggest that JN.1 is one of the most immune-evading variants to date. S:L455S can contribute to increased immune evasion, which partly explains the increased Re of JN.1."
From the abstract:
Speculation: It may not be a good idea to target primarily the spike protein, which seems to be mutating faster than vaccines can be developed. From the very beginning, Cuba instead targeted the receptor-binding domain of the virus, which doesn't appear to be as mutatable. All the Cuban C19 vaccines are based on this principle.
An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen (PubMed/Epub, Aug 8, 2022)
Cubas coronavacciner: »Vi vidste, at vi havde gode chancer« (Cuba-venner.dk, June 27, 2021)
Finally, some info on the new mono-valent vax and current variants. I've been waiting for this.
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants
Also, I'm looking at getting the flu vax too. It's ramping up strongly here in Calif. Covid-19 is at a somewhat higher level but isn't ramping as much. Ideally, I want to get the shots 1 to 2 months prior to the transmission peaks since they both wane rather quickly at three months. So probably in the next 1 to 2 weeks.
The monovalent XBB.1.5 doesn't seem to offer much immunity against the new variant JN.1, according to a new study from the The Sato Lab (Kei Sato).
From a tweet:
"JN.1 shows a robust resistance to monovalent XBB.1.5 vaccine sera. These results suggest that JN.1 is one of the most immune-evading variants to date. S:L455S can contribute to increased immune evasion, which partly explains the increased Re of JN.1."
From the abstract:
BA.2.86 has evolved and its descendant, JN.1 (BA.2.86.1.1), emerged in late 2023. JN.1 harbors S:L455S and three mutations in non-S proteins. S:L455S is a hallmark mutation of JN.1: we have recently shown that HK.3 and other "FLip" variants carry S:L455F, which contributes to increased transmissibility and immune escape ability compared to the parental EG.5.1 variant.
Virological characteristics of the SARS-CoV-2 JN.1 variant (bioRxiv, Dec 8, 2023)
Speculation: It may not be a good idea to target primarily the spike protein, which seems to be mutating faster than vaccines can be developed. From the very beginning, Cuba instead targeted the receptor-binding domain of the virus, which doesn't appear to be as mutatable. All the Cuban C19 vaccines are based on this principle.
An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen (PubMed/Epub, Aug 8, 2022)
Cubas coronavacciner: »Vi vidste, at vi havde gode chancer« (Cuba-venner.dk, June 27, 2021)
Last edited: